By: James Pitt  Apr. 19, 2018

Baxdela (delafloxacin), by Melinta Pharmaceuticals, is a fluoroquinolone antibiotic recently approved for treatment of acute bacterial skin and skin structure infections (ABSSSI). Dexur previously examined Baxdela’s potential for readmissions in Florida. Clinical trials in March 2018 and December 2017 found lower rates of treatment discontinuation with Baxdela than with vancomycin plus aztreonam. This is significant because initial treatment failure is common in serious skin infections. According to a 2011 retrospective study, initial antibiotic therapy failed in 22.4% of patients with ABSSSI.

By: Jeffrey Maser  Mar. 19, 2018

Baxdela, by Melinta Therapeutics, was recently approved by the FDA and has been launched to treat serious bacterial infections. Baxdela (delafloxacin) was approved for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by gram-positive and gram-negative organisms. A common example of a gram-positive organism is Methicillin-resistant Staphylococcus aureus (MRSA) while an example of a widely known gram-negative organism is Escherichia coli (E.coli). The options for treating ABSSSI have been limited but Baxdela was found to be effective in treating ABSSSI compared to the standard combined treatment of antibiotics vancomycin and aztreonam.